Sunshine Biopharma annual stock-based compensation
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Sunshine Biopharma Stock-Based Compensation Growth & History (SBFM)
Sunshine Biopharma's stock-based compensation was $271,930 for fiscal 2020.
View full Sunshine Biopharma company overviewSunshine Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | $271,930 | −$5,322 | −1.92% |
| 2019 | 2019-12-31 | $277,252 | −$477,963 | −63.29% |
| 2018 | 2018-12-31 | $755,215 | $234,944 | +45.16% |
| 2017 | 2017-12-31 | $520,271 | $20,874 | +4.18% |
| 2016 | 2016-12-31 | $499,397 | $382,897 | +328.67% |
| 2015 | 2015-12-31 | $116,500 | −$1.1M | −90.74% |
| 2014 | 2014-12-31 | $1.3M | $11,696 | +0.94% |
| 2013 | 2013-12-31 | $1.2M | $973,435 | +356.73% |
| 2012 | 2012-12-31 | $272,875 | $5,490 | +2.05% |
| 2011 | 2011-12-31 | $267,385 | $30,185 | +12.73% |
| 2010 | 2010-12-31 | $237,200 | — | — |
Sunshine Biopharma quarterly stock-based compensation
Q1.10
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2016 | 2016-12-31 | $79,897 | $79,897 | — |
| Q3 2016 | 2016-09-30 | $156,500 | $156,500 | — |
| Q2 2016 | 2016-06-30 | $263,000 | $146,500 | +125.75% |
| Q1 2016 | 2016-03-31 | $0 | $0 | — |
| Q4 2015 | 2015-12-31 | $0 | −$172,021 | — |
| Q3 2015 | 2015-09-30 | $0 | −$225,185 | — |
| Q2 2015 | 2015-06-30 | $116,500 | −$476,900 | −80.37% |
| Q1 2015 | 2015-03-31 | $0 | −$267,400 | — |
| Q4 2014 | 2014-12-31 | $172,021 | −$357,979 | −67.54% |
| Q3 2014 | 2014-09-30 | $225,185 | $145,185 | +181.48% |
| Q2 2014 | 2014-06-30 | $593,400 | $533,400 | +889.00% |
| Q1 2014 | 2014-03-31 | $267,400 | −$308,910 | −53.60% |
| Q4 2013 | 2013-12-31 | $530,000 | $524,000 | +8733.33% |
| Q3 2013 | 2013-09-30 | $80,000 | −$186,875 | −70.02% |
| Q2 2013 | 2013-06-30 | $60,000 | $60,000 | — |
| Q1 2013 | 2013-03-31 | $576,310 | $576,310 | — |
| Q4 2012 | 2012-12-31 | $6,000 | −$237,385 | −97.53% |
| Q3 2012 | 2012-09-30 | $266,875 | $266,875 | — |
| Q2 2012 | 2012-06-30 | $0 | −$12,000 | — |
| Q1 2012 | 2012-03-31 | $0 | −$12,000 | — |
| Q4 2011 | 2011-12-31 | $243,385 | — | — |
| Q3 2011 | 2011-09-30 | $0 | −$663,974 | — |
| Q2 2011 | 2011-06-30 | $12,000 | −$1.6M | −99.24% |
| Q1 2011 | 2011-03-31 | $12,000 | $12,000 | — |
| Q3 2010 | 2010-09-30 | $663,974 | — | — |
| Q2 2010 | 2010-06-30 | $1.6M | — | — |
| Q1 2010 | 2010-03-31 | $0 | — | — |
Sunshine Biopharma stock-based compensation trends
Over the last five fiscal years, Sunshine Biopharma's stock-based compensation increased from $116,500 to $271,930, a change of $155,430. The latest reported quarter, Q4 2016, shows $79,897.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sunshine Biopharma source filings ↗